Search the Newsroom
Filter By
Showing 771 - 780 of 2907 results
Advanced Sickle Cell Disease Therapies—Including a Cure—Are on the Horizon
Case: Langston is a 12-year-old with sickle cell disease whom you have followed in your practice since infancy.
Promising Use for Antibody Treatment for EoE
Two recent studies show dupilumab improves eosinophilic esophagitis symptoms and pathology for adolescents and young adults.
The Next Frontier of Care for VEO-IBD
Very early onset inflammatory bowel disease was virtually unheard of just a decade ago. Today, a variety of personalized therapies exist, and potential curative gene therapies are on the horizon.
Vaccine News & Notes — February 2023
Learn about the decrease in numbers of completely unvaccinated children in the CDC’s annual survey, and check out “The Vaccine Quest,” a free online course for anyone who wants to find out more about vaccines.
Pancreatic Case Study
Continued surveillance after pancreatic solid pseudopapillary tumor and pancreatic insufficiency is important – even after treatment.
Motility Case Study
When rumination and gastroparesis collide in patients at Children’s Hospital of Philadelphia, a personalized treatment plan is developed.
Alumni Notes Winter 2023
Welcome back to the annual Chief Residents update column. Our residents have been working so hard during the pandemic and now the unprecedented fall viral surge.
Fellow's Corner: Until a Cure, We Must Do Better to Reduce SCD Risks
Sickle cell disease (SCD) is the most common inherited blood disorder worldwide; with patients experiencing acute or chronic pain, and increased risk of bacterial infections, organ damage, and stroke.
Growing Mini-Organs for Personalized GI Solutions
Researchers from CHOP and Penn are working to perfect 3D models of GI disease and create more personalized treatments for patients.
News at CHOP: Winter 2023
Fall 2022 saw the loss of two more CHOP luminaries as Ralph Wetmore, MD, former Chief of Otolaryngology, and Audrey Evans, MD, former Chief of Oncology, died in September.